These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34032171)

  • 21. Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions.
    Razonable RR
    Expert Opin Biol Ther; 2023; 23(7):619-631. PubMed ID: 37318043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19.
    Razonable RR; Pawlowski C; O'Horo JC; Arndt LL; Arndt R; Bierle DM; Borgen MD; Hanson SN; Hedin MC; Lenehan P; Puranik A; Seville MT; Speicher LL; Tulledge-Scheitel SM; Venkatakrishnan AJ; Wilker CG; Badley AD; Ganesh R
    EClinicalMedicine; 2021 Oct; 40():101102. PubMed ID: 34485873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis.
    San Filippo S; Crovetto B; Bucek J; Nahass RG; Milano M; Brunetti L
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac080. PubMed ID: 35299987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
    Bierle DM; Ganesh R; Tulledge-Scheitel S; Hanson SN; Arndt LL; Wilker CG; Razonable RR
    J Infect Dis; 2022 Feb; 225(4):598-602. PubMed ID: 34791298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities.
    Monday LM; Brar I; Alangaden G; Ramesh MS
    J Clin Pharm Ther; 2022 Sep; 47(9):1438-1443. PubMed ID: 35633095
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilities.
    Tulledge-Scheitel S; Bell SJ; Larsen JJ; Bierle DM; Takahashi P; Moehnke DE; Destro Borgen MJ; Springer DJ; Reinschmidt KJ; Baumbach LJ; Matoush JA; Heyliger A; Hanson SN; Razonable RR; Ganesh R
    J Am Geriatr Soc; 2021 Apr; 69(4):868-873. PubMed ID: 33619724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate Coronavirus Disease 2019 (COVID-19): A Real-World Experience.
    Verderese JP; Stepanova M; Lam B; Racila A; Kolacevski A; Allen D; Hodson E; Aslani-Amoli B; Homeyer M; Stanmyre S; Stevens H; Garofalo S; Henry L; Venkatesan C; Gerber LH; Motew SJ; Jones JS; Younossi ZM
    Clin Infect Dis; 2022 Mar; 74(6):1063-1069. PubMed ID: 34166513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study.
    Sherman G; Lamb GS; Sharma TS; Lloyd EC; Nagel J; Dandam NN; Oliveira CR; Sheikha HS; Anosike BI; Lee P; Vora SB; Patel K; Sue PK; Rubbab B; Yarbrough AM; Ganapathi L; Nakamura MM
    J Pediatric Infect Dis Soc; 2023 Apr; 12(3):152-155. PubMed ID: 36928172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience.
    Chilimuri S; Mantri N; Gurjar H; Youthjug KA; Sun H; Gongati S; Zahid M; Ronderos DM; De La Cruz A; Varanasi P; Shin D; Nayudu SK
    J Natl Med Assoc; 2022 Jan; 113(6):701-705. PubMed ID: 34521513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19.
    Ruggeri M; Signorini A; Caravaggio S
    PLoS One; 2023; 18(2):e0279022. PubMed ID: 36763607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019.
    Razonable RR; Ganesh R; Bishop RK; Culbertson TL; Destro Borgen M; Hedin MC; Hopkins LH; Jackson TA; Larsen JJ; Matoush JA; Moehnke DE; Olson SM; Peterson KM; Rosedahl J; Philpot LM
    J Patient Exp; 2022; 9():23743735221105673. PubMed ID: 35769314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of COVID-19 monoclonal antibodies on clinical outcomes: A retrospective cohort study.
    R Nagler A; Horwitz LI; Jones S; Petrilli CM; Iturrate E; Lighter JL; Phillips M; Bosworth BP; Polsky B; Volpicelli FM; Dapkins I; Viswanathan A; François F; Kalkut G
    Am J Health Syst Pharm; 2022 Dec; 79(24):2222-2229. PubMed ID: 36242772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients.
    Piccicacco N; Zeitler K; Montero J; Kumar A; Lakshmi S; Kim K; Wein D; Vasey T; Vasey M; Oxner A
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab292. PubMed ID: 34258319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.
    Amanam I; Yao J; Puing A; Tsai NC; Samuels D; Ngo D; Ho S; Ali H; Aribi A; Arslan S; Artz A; Htut M; Koller P; Salhotra A; Sandhu K; Nikolaenko L; Pawlowska A; Shouse G; Stein A; Marcucci G; Forman S; Nakamura R; Dadwal S; Al Malki MM
    Cancer Med; 2023 May; 12(10):11248-11253. PubMed ID: 37081733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Bariola JR; McCreary EK; Wadas RJ; Kip KE; Marroquin OC; Minnier T; Koscumb S; Collins K; Schmidhofer M; Shovel JA; Wisniewski MK; Sullivan C; Yealy DM; Nace DA; Huang DT; Haidar G; Khadem T; Linstrum K; Seymour CW; Montgomery SK; Angus DC; Snyder GM
    Open Forum Infect Dis; 2021 Jul; 8(7):ofab254. PubMed ID: 34250192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective Case-Control Study of REGEN-COV (Casirivimab and Imdevimab) Therapy for Patients with COVID-19 and Cancer Using the United States MarketScan® Database.
    Takemoto K
    Oncology; 2024; 102(3):195-205. PubMed ID: 37666220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: A single-center, propensity-matched cohort study.
    Rhudy C; Bochenek S; Thomas J; St James G; Zeltner M; Platt T
    Am J Health Syst Pharm; 2023 Jan; 80(3):130-136. PubMed ID: 36264659
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients.
    Yetmar ZA; Beam E; O'Horo JC; Ganesh R; Bierle DM; Brumble L; Seville MT; Razonable RR
    Open Forum Infect Dis; 2021 Jun; 8(6):ofab255. PubMed ID: 34631921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Maternal Perinatal SARS-CoV-2 Infection With Neonatal Outcomes During the COVID-19 Pandemic in Massachusetts.
    Angelidou A; Sullivan K; Melvin PR; Shui JE; Goldfarb IT; Bartolome R; Chaudhary N; Vaidya R; Culic I; Singh R; Yanni D; Patrizi S; Hudak ML; Parker MG; Belfort MB
    JAMA Netw Open; 2021 Apr; 4(4):e217523. PubMed ID: 33890989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital.
    Pannier J; Nass N; Yaakoub MK; Stelzner FMM; Veit S; Kalomoiri M; Yassine M; Behre G
    Infect Dis Rep; 2023 Feb; 15(1):125-131. PubMed ID: 36826353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.